Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
ADVENTRX Submits Exelbine™ New Drug Application
Date:11/3/2010
g developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding FDA acceptance of the Exelbine NDA for review, approval of Exelbine based on that 505(b)(2) NDA submission and patent protection for Exelbine. Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: the risk that the FDA does not accept the Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; the potential that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial; the risk that results of future stability testing on samples of Exelbine do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; th
'/>"/>
| SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
(Date:6/19/2013)... 2013 Echo Therapeutics, Inc. (Nasdaq: ... ® CGM System as a non-invasive, wireless ... of a previously announced underwritten public offering of ... full exercise of the over-allotment option to purchase ... the public of $2.70 per share. The total gross ...
(Date:6/19/2013)... 19, 2013 Eli Lilly and Company (NYSE: ... two illegal scams, purportedly using the name of the ... actively targeting the public through postal mail solicitations and ... connection to any foreign lottery organizations and do not ... job-seeking victims of the scam. The activities described in ...
(Date:6/19/2013)... 19, 2013 Reportlinker.com ... research report is available in its ... Investments and M&A Deals and Trends ... http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... and Trends for May 2013 in ...
Breaking Medicine Technology:Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 2Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 3Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 3Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 4Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 6Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 7Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 8Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 9Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 10Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 11Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 12Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 13[0] Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter[0] Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests[0] Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals
... , April 28 Xlumena, a privately ... announced it has received clearance from the US Food ... Device. The NAVIX™ Device is an advanced endoscopy system, ... and dilation balloons and two guidewire ports, designed to ...
... The biopharma mega-mergers that grabbed headlines last year - Roche ... in the critical post-integration period and the acquiring companies are finding out ... for final verdicts, but clearly one M&A issue that continues to create ... , , ...
Cached Medicine Technology:FDA Clears Xlumena's NAVIX(TM) Access Device 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 3(Date:6/19/2013)... York, NY (PRWEB) June 19, 2013 Citi Bike ... There’s no way for Dr. David Perna to know for sure ... service, but he’s happy that they’ll have the option. In ... healthier lives—especially if it might also make it more convenient for ... Dr. Perna is the Director of Complimentary Alternative Medicine at Back ...
(Date:6/19/2013)... June 19, 2013 According to a June ... Weekend Sunburn,” it is not uncommon for a person to ... months. A person is likely to forget to reapply sunscreen ... is both dry and itchy. When this occurs, it is ... goo.gl/gDyjP). , “Most people do not realize that milk contains ...
(Date:6/19/2013)... surgery have had a significant impact on survival ... injuries, including burns. Patients who survive the ... greatest risk from infections particularly the overwhelming, ... from inflammation-induced multiorgan failure. Now, a device ... measures the movement of key immune cells may ...
(Date:6/19/2013)... is believed to be the largest follow-up record of ... a movement disorder that can cause crippling muscle ... success rates and lasting benefits. , Michele Tagliati, MD, ... Medical Center,s Department of Neurology, and Ron L. Alterman, ... Israel Deaconess Medical Center in Boston, published the study ...
(Date:6/19/2013)... of three important studies have been published in the ... the Congress of Neurological Surgeons . The ... , a part of Wolters Kluwer Health . ... artificial neural networks (ANNs) may improve the ability to ... study in the June Neurosurgery supports increased ...
Breaking Medicine News(10 mins):Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Skin Care – How to treat Sunburn 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3[0] New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan[0] Skin Care – How to treat Sunburn[0] Restoring appropriate movement to immune cells may save seriously burned patients[0] Long-term study reports deep brain stimulation effective for most common hereditary dystonia[0] Neurosurgery publishes findings of 3 important studies in June issue
... LAKE FOREST, Ill. and MINNEAPOLIS , ... Fitness Corporation (NYSE AMEX: FIT ) today announced that ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in ... http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On January 21, 2010 , ...
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... ... San Francisco,s famed PIER 39 docks, was successfully rescued, rehabilitated and released back to the ... assembled at Rodeo Beach in the Marin Headlands, Sausalito, CA to watch as "Abagnale" made ... ...
... focus of new laws, online testing and Super Bowl plug ... improve treatment of concussions in youth sports are making headway ... in scholastic sports will get big play Sunday at Super ... can help athletic trainers and doctors determine when it,s safe ...
... LOS ANGELES , Feb. 5 Food 4 ... to support children,s hospitals in the communities its stores serve in ... Chicago area. In addition, the supermarket chain,s Foods Co ... California . , Customers and team members can support their ...
... Finding may further understanding of common diseases, researchers say , ... map of areas of the human genome that control which ... a finding that may advance understanding of the genetic ... the human genome is uncharted territory -- entire stretches of ...
Cached Medicine News:Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:Concussion Awareness for Young Athletes Gets Big Play 2Health News:Food 4 Less Charitable Campaign to Benefit Children's Hospitals 2Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting PeriodAVMA Calls for Stronger Animal Disease Traceability SystemEntangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the OceanConcussion Awareness for Young Athletes Gets Big PlayFood 4 Less Charitable Campaign to Benefit Children's HospitalsGenome Mapped for Type 2 Diabetes
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
... It's easy on delicate urethral ... and hydrophilic coating provide nearly ... gel. It's easy to maintain ... catheter with its own sterile ...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |